Skip to content
OBN white logo.

Catalysing Success in Life Sciences

OBN is a not-for-profit membership network that catalyses growth for the life sciences industry. Whether you’re an emerging entrepreneur, R&D SME, investor, analyst, pharma company, science park, TTO or technology / professional services organisation, we are here to give you opportunities to meet, learn, and grow. Read more about how we can help you to:

Create Connections Secure Investment Save Time & Money Join OBN
Patron
Ipsen logo
Sponsors
BDO logo
Bruntwood SciTech logo
Fisher Scientific logo
Merck logo
Milton Park logo
Parners& logo
Penningtons Manches Cooper Logo
Precision for Medicine logo
Syneos Health logo
ThermoFisher Scientific logo
Taylor Wessing Logo
Zyme Communications logo.
EBD Group Logo
Venner Shipley Company Logo

Join us at the next OBN event

Make connections and keep up to date with the latest life sciences industry innovations. View upcoming OBN and Member events.

We pride ourselves on supporting our members to catalyse their success.

We do this by keeping the life sciences community connected and informed, making us an essential partner.

But don’t take our word for it, here is what our members and partners say.

“At Oxford Endovascular we feel that OBN’s well informed team is really invested in our journey, supporting us as the business develops.”

Mike Karim Oxford Endovascular , CEO
Oxford Endovascular Logo

“Through OBN we can make valuable connections with potential customers, keeping them informed about Biosynth’s products and services. Other advantages to being an OBN member include discounted rates for events and conference attendance.”

Adrian Hery Barranco Biosynth, Marketing & Business Development Officer
Biosynth Logo

“I’ve met a number of amazing people through OBN, who are all so open to sharing their experience and helping to support emerging biotechs. I’d encourage everyone to join in, whether a seasoned industry insider, an emerging biotech with exciting science, or a sponsor aiming to build their brand and support new biotech – OBN is great!”

Nick Pumphrey Etcembly, CSO
Etcembly Logo

Latest News

General

Imperial and Bruntwood SciTech Join Forces on New Innovation Workspace in London’s White…

Read More
General
Glox Therapeutics Awarded £1M PACE Grant to Accelerate Development of Precision Antibiotics Aga…
General
New Trustees appointed to the Rosalind Franklin Institute’s Board
General
Coulter Partners strengthens leadership at IMU Biosciences with placements of Chief Executive O…
General
Novel procedure for cell delivery in Rinri Therapeutics’ first clinical trial described in peer…
More articles this way